Mocertatug rezetecan

Phase 3

GSK

Mocertatug rezetecan is one of 48 therapeutic programs targeting Neoplasms, Endometrial. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Neoplasms, EndometrialRecruiting

Solid TumorRecruiting

Ovarian NeoplasmsRecruiting

Neoplasms, EndometrialPhase 3

Recruiting

Solid TumorPhase 1

Recruiting

Ovarian NeoplasmsPhase 3

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Mocertatug rezetecan

GSK

Phase 3

1 2

Fludara

Sanofi

Preclinical

1 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 6

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 7

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 9

Tulmimetostat

Novartis

Preclinical

1 10

Carboplatin AUC-5

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Neoplasms, Endometrial

NCT07286331

Q4 2029

Phase 3Recruiting

Ovarian Neoplasms

NCT07286266

Phase 1Recruiting

Solid Tumor

NCT06431594

Q3 2031

Phase 3Not yet recruiting

Neoplasms, Endometrial

NCT07684599

Q4 2032

Phase 3Not yet recruiting

Ovarian Neoplasms

NCT07694427

Clinical

Trials by Indication[1]

Ovarian Neoplasms3 trials

A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-Sensitive Ovarian Cancer

Not yet recruiting· GSK logo

GSK·Phase 3·NCT07684612·690 enrolled

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With or Without Bevacizumab in Comparison to Active Observation With or Without Bevacizumab as Maintenance Treatment in Participants With Newly Diagnosed FIGO Stage III/IV Non-Homologous Recombination Deficient Ovarian Cancer

Not yet recruiting· GSK logo

GSK·Phase 3·NCT07694427·720 enrolled

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer

Recruiting· GSK logo

GSK·Phase 3·NCT07286266·450 enrolled

Neoplasms, Endometrial2 trials

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan in Combination With Immune Checkpoint Inhibition for Maintenance Treatment of Participants With Mismatch Repair Proficient (MMRp) Endometrial Cancer

Not yet recruiting· GSK logo

GSK·Phase 3·NCT07684599·610 enrolled

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy

Recruiting· GSK logo

GSK·Phase 3·NCT07286331·600 enrolled

Solid Tumor1 trial

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors

Recruiting· GSK logo

GSK·Phase 1·NCT06431594·675 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Mocertatug rezetecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mocertatug rezetecan. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: GSK

Mocertatug rezetecan

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q4 2029

Q3 2031

Q4 2032

Trials by Indication[1]

Ovarian Neoplasms3 trials

Neoplasms, Endometrial2 trials

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News